NCT06828211

Trans-resveratrol's Influence on the Development of CHF in Early Postmenopausal Women with HTN and Reduced BMD

Prospective Open Randomized Controlled Trial on the Effectiveness and Tolerability of Trans-resveratrol (derived from Polygonum Cuspidatum Root Extr.) on the Development of CHF in Postmenopausal Women with HTN and Reduced BMD

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: OMNIFARMA LLC · Industry
• Sex: Female
• Age: 45 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

1. To measure the ability of trans-resveratrol to influence the development of chronic heart failure (CHF) in women in the early postmenopausal period (1-4 years) with hypertension (HTN) and reduced bone mineral density (BMD). 2. To evaluate the safety of long-term use of trans-resveratrol in an amount of 500 mg per day. 3. To develop modern measures to influence the development of CHF in women of this group

Conditions

• Heart Failure
• Arterial Hypertension
• Osteopenia
• Menopause

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Trans-resveratrol extract from Polygonum Cuspidatum	Trans-resveratrol extract from Polygonum Cuspidatum
OTHER	Placebo	Placebo

Timeline

• Start date: 2024-09-09
• Primary completion: 2025-02-09
• Completion: 2025-03-31
• First posted: 2025-02-14
• Last updated: 2025-03-19

Locations

1 site across 1 country: Ukraine